Pulse Biosciences (NASDAQ:PLSE) CTO Darrin Uecker Sells 20,000 Shares

Key Points

• Darrin Uecker, CTO of Pulse Biosciences, sold 20,000 shares at an average price of $16.21, totaling $324,200, which reduced his ownership in the company by 14%.
• Following recent insider sales, Pulse Biosciences' stock saw a 13.8% increase, trading at $18.52 with a market capitalization of $1.25 billion.
• Pulse Biosciences reported earnings of ($0.28) EPS for the last quarter, missing analyst estimates, while the stock has a consensus "Buy" rating with a target price of $22.00.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) CTO Darrin Uecker sold 20,000 shares of the business's stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $16.21, for a total transaction of $324,200.00. Following the completion of the sale, the chief technology officer owned 122,872 shares in the company, valued at $1,991,755.12. This represents a 14.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Darrin Uecker also recently made the following trade(s):

• On Monday, September 15th, Darrin Uecker sold 25,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $15.77, for a total transaction of $394,250.00.
• On Thursday, September 11th, Darrin Uecker sold 25,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $14.78, for a total transaction of $369,500.00.

Pulse Biosciences Stock Performance

PLSE stock traded down $0.20 during mid-day trading on Monday, reaching $17.41. 149,539 shares of the stock traded hands, compared to its average volume of 179,331. Pulse Biosciences, Inc has a one year low of $13.77 and a one year high of $25.00. The stock has a market capitalization of $1.17 billion, a PE ratio of -16.56 and a beta of 1.68. The business has a 50-day moving average price of $15.57 and a two-hundred day moving average price of $16.14.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).

Wall Street Analysts Forecast Growth

Separately, Oppenheimer initiated coverage on shares of Pulse Biosciences in a report on Monday, July 7th. They issued an "outperform" rating and a $22.00 price target on the stock. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Pulse Biosciences presently has an average rating of "Buy" and a consensus target price of $22.00.

Hedge Funds Weigh In On Pulse Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of PLSE. BNP Paribas Financial Markets lifted its position in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after buying an additional 680 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Pulse Biosciences by 68.0% during the 1st quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after buying an additional 1,261 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Pulse Biosciences by 6.3% during the 1st quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock valued at $440,000 after buying an additional 1,614 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Pulse Biosciences by 24.6% during the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock valued at $143,000 after buying an additional 1,778 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after purchasing an additional 2,156 shares in the last quarter. Institutional investors and hedge funds own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.